Celiac Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Celiac Disease Pipeline Drugs Assessment
Celiac Diseaseis a genetic autoimmune disease. It is caused due to the consumption of protein called gluten, which is found in barley, wheat,and rye. It enables damage the finger-like villi of small intestine and body will be unable to absorb nutrients into thebloodstream that leads to malnutrition. Symptoms of celiac disease include food allergy, watery and itchy eyes, difficulty in breathing, nausea, abdominal pain, mouth ulcers.
Celiac disease is diagnosed by serology tests and genetic tests. Treatment includes strict gluten-free diet. There are no FDA approved drugs to treat celiac disease.
By Drugs, Celiac Disease pipeline drugs are segmented as:
By Route of Administration, Celiac Disease pipeline drugs are segmented as:
By Trial Phase, Celiac Diseasepipeline drugs are segmented as:
- Phase 1
- Phase 2
- Phase 3
- Phase 4
By Company, Celiac Diseasepipeline drugs are segmented as:
- AMYRA Biotech AG (Switzerland)
- Avaxia Biologics, Inc. (U.S.)
- Calypso Biotech SA (Switzerland)
- Provid Pharmaceuticals Inc. (U.S.)
- Sitari Pharmaceuticals (U.S.)
- Cour Pharmaceuticals (U.S.)
- Glenmark Pharmaceuticals Ltd. (India)
- Innovate Biopharmaceuticals (U.S.)
- In November 2017, ImmusanT, Inc.raised $40 million Series C equity financing from ARCH Venture Partners and Vatera Healthcare Partners to proceedPhase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen DQ2.5 (HLA-DQ2.5) immune recognition gene.
- In February 2016, Innovate Biopharmaceuticals Inc., completed an agreement to license Alba Therapeutics assets relating to larazotide acetate, a tight junction regulator, progressing toward Phase 3 clinical trials for the treatment of celiac disease.
- In December 2015, Takeda Pharmaceutical Company Limited and Cour Pharmaceutical Development Company, Inc. entered into a partnership to research and develop novel immune modulating therapies for the potential treatment of celiac disease
- In March 2015, Falk Pharma and Zedira entered into a collaboration to perform Phase 1 clinical trials of ED1227, a direct-acting inhibitor of tissue transglutaminase. The small molecule targets the dysregulated transglutaminase within the small intestine in order to dampen the immune response to gluten which drives the celiac disease process.
Celiac Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Celiac Disease treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Celiac Disease pipeline drugs development. This report studies the dynamics of the Celiac Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Celiac Disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Key Features of the Report:
- Provides the information related to universities and research institutes working in the therapeutics development
- Report comprehensively covers the all active and discontinued studies
- Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
- Presents the prominent targets for drug development in each stage of clinical trial
- Provides the in-depth analysis on each drug candidates in the clinical trial phases